Tal Zvi Zaks - 10 May 2021 Form 4 Insider Report for Moderna, Inc. (MRNA)

Role: Chief Medical Officer
Signature: /s/ Brian Sandstrom, as Attorney-in-Fact
Issuer symbol: MRNA
Transactions as of: 10 May 2021
Net transactions value: -$536,806
Form type: 4
Filing time: 11 May 2021, 16:12:52 UTC
Next filing: 13 May 2021
SEC: View on sec.gov

Transactions Table

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Ownership	Footnotes
transaction	MRNA	Common Stock	Options Exercise	$44,811	+3,670		$12.21^*	3,670	10 May 2021	Direct	F1
transaction	MRNA	Common Stock	Sale	$93,960	-600	-16%	$156.60	3,070	10 May 2021	Direct	F1, F2
transaction	MRNA	Common Stock	Sale	$155,118	-985	-32%	$157.48	2,085	10 May 2021	Direct	F1, F3
transaction	MRNA	Common Stock	Sale	$251,825	-1,585	-76%	$158.88	500	10 May 2021	Direct	F1, F4
transaction	MRNA	Common Stock	Sale	$31,926	-200	-40%	$159.63	300	10 May 2021	Direct	F1, F5
transaction	MRNA	Common Stock	Sale	$16,164	-100	-33%	$161.64	200	10 May 2021	Direct	F1
transaction	MRNA	Common Stock	Sale	$32,624	-200	-100%	$163.12	0	10 May 2021	Direct	F1, F6

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Underlying Class	Amount	Exercise Price	Ownership	Footnotes
transaction	MRNA	Stock Option (Right to Buy)	Options Exercise	$0	-3,670	-2.6%	$0.000000	137,612	10 May 2021	Common Stock	3,670	$12.21	Direct	F1, F7

* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id	Content
F1	The reported transaction was effected pursuant to a Rule 10b5-1 trading plan adopted on March 13, 2020.
F2	The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $155.99 to $156.87. Full information regarding the number of shares sold at each separate price can be furnished to the SEC staff upon request.
F3	The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $157.03 to $158.01. Full information regarding the number of shares sold at each separate price can be furnished to the SEC staff upon request.
F4	The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $158.28 to $159.27. Full information regarding the number of shares sold at each separate price can be furnished to the SEC staff upon request.
F5	The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $159.58 to $159.68. Full information regarding the number of shares sold at each separate price can be furnished to the SEC staff upon request.
F6	The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $163.00 to $163.25. Full information regarding the number of shares sold at each separate price can be furnished to the SEC staff upon request.
F7	229,358 of the options will vest over 4 years (25% on the first anniversary of the grant date of October 3, 2017, then quarterly for the next 3 years). 137,614 of the options will vest over 5 years (25% on the second anniversary of the grant date of October 3, 2017, then quarterly for the next 3 years). 91,743 of the options will vest over 6 years (25% on the third anniversary of the grant date of October 3, 2017, then quarterly for the next 3 years).